PROTOCOL OUTLINE: Donor bone marrow, peripheral blood, or umbilical cord blood is processed
to harvest CD34+ cells.
Patients receive preparative cytoreductive therapy comprising total body irradiation on day
-6; cyclophosphamide IV over 2 hours on days -5 to -2; fludarabine IV over 30 minutes on
days -5 to -2; methylprednisone IV on days -5 to 24; anti-thymocyte globulin IV over 4-6
hours on days -5 to -1; cyclosporine IV over 2 hours every 12 hours (every 8 hours for
patients less than 40 kg in weight) on days -3 to 180, and then tapering in the absence of
graft-versus-host disease; hematopoietic cell transplantation on day 0; and filgrastim
(G-CSF) IV starting on day 1 and continuing until blood counts recover.
Patients are followed at days 60, 90, and 180, and then annually for 3 years.
Primary Purpose: Treatment
John E. Wagner, Jr.
University of Minnesota - Clinical and Translational Science Institute
|University of Minnesota Cancer Center||Minneapolis, Minnesota 55455|